[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-moderna-sinks-another-8-even-as-lead-investigator-calls-melanoma-vaccine-data-transformational-EN":150},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[],{"post":151,"seo":187,"relatedPosts":193,"suggestedPosts":270},{"id":152,"title":153,"date":154,"modified":155,"excerpt":156,"content":157,"wordCount":158,"lang":159,"uri":160,"slug":161,"cloudinaryAssetId":162,"featuredImageOriginalUrl":163,"featuredImageMetadata":164,"author":167,"editor":173,"categories":178,"relatedPosts":184,"seo":185},145509,"Moderna Sinks Another 8% Even as Lead Investigator Calls Melanoma Vaccine Data “Transformational”","2026-10-26T19:28:09","2026-10-26T19:28:17","\u003Cp>A real win for melanoma patients, and still a pricey stock\u003C\u002Fp>\n","\n\u003Ch2 id=\"h-key-takeaways\" class=\"wp-block-heading\">Key Takeaways\u003C\u002Fh2>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>Moderna shares fell another 8% this morning. On Saturday it and its partner Merck presented full Phase 3 data showing their personalized melanoma vaccine cut the risk of recurrence or death by 42%.\u003C\u002Fli>\n\n\n\n\u003Cli>The lead investigator called the results transformational for cancer, but the stock was priced for more than one melanoma win, and it still is.\u003C\u002Fli>\n\n\n\n\u003Cli>Moderna still trades far above its five-year average forward price\u002Fsales multiple, while analysts expect just $3.3 billion of revenue in 2028.\u003C\u002Fli>\n\n\n\n\u003Cli>Longer follow-up and overall-survival data are the next tests, with Merck reporting on Oct. 29 and Moderna on Nov. 6.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cstrong>Moderna (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=128680956&tid=591065499\">MRNA\u003C\u002Fa>)\u003C\u002Fstrong> stock fell another 8% this morning. That’s despite Dr. Georgina Long calling the melanoma vaccine data she presented on Saturday “something so transformational for cancer.”\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Long, of Melanoma Institute Australia, led the Phase 3 trial of intismeran, the personalized vaccine Moderna is developing with \u003Cstrong>Merck (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=288502&tid=2629738\">MRK\u003C\u002Fa>)\u003C\u002Fstrong>. The stock had already lost about 19% on Thursday and Friday after an \u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmoderna-sinks-18-on-apparent-leak-of-embargoed-phase-3-melanoma-vaccine-data\">apparent leak of the results\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-what-exactly-happened\" class=\"wp-block-heading\">What exactly happened\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">At Saturday’s European Society for Medical Oncology meeting, Long presented results for patients who had already had surgery for melanoma. The trial tested intismeran plus Merck’s Keytruda against Keytruda alone:\u003C\u002Fp>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>A 42% cut in the risk of recurrence or death\u003C\u002Fli>\n\n\n\n\u003Cli>A 38% cut in the risk of distant metastasis or death\u003C\u002Fli>\n\n\n\n\u003Cli>A stronger benefit after six months\u003C\u002Fli>\n\n\n\n\u003Cli>Overall-survival data still to come\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">That matters. Even with Keytruda, 44% of stage III patients see their cancer come back or die within five years. Three Phase 3 trials that added other immunotherapies to drugs like Keytruda all failed.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cstrong>TIKR tracks 23 analysts on Moderna. How many say “Buy”?\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">See the full breakdown of Buy, Hold, and Sell ratings on Moderna, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. \u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fvaluation-model-builder?ref=tikrblog\">See Moderna’s Analyst Ratings\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-the-bar-was-higher-for-the-stock\" class=\"wp-block-heading\">The bar was higher for the stock\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">In Moderna’s Phase 2 trial, the cut in risk was 49% after five years of follow-up. The stock also ran up ahead of this readout, helped by the \u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmoderna-stock-soared-14-as-nih-plans-covid-style-push-for-cancer-vaccines\">NIH’s plan for a COVID-style push on cancer vaccines\u003C\u002Fa>. So 42% read as a step down.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">At Friday’s close, Moderna traded at 42x forward sales. That’s down from 52x on Oct. 21 but still far above its five-year average of 7.7x.\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3024\" height=\"2016\" data-public-id=\"images\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y.png\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3024,h_2016,c_scale\u002Ff_webp,q_auto\u002Fv1793018831\u002Fimages\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y.png?_i=AA\" alt=\"Line chart from TIKR of Moderna's forward (NTM) price\u002Fsales, last 5 years.\" class=\"wp-post-145509 wp-image-145507\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1793018831\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1793018831\u002Fimages\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y.png?_i=AA 3024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793018831\u002Fimages\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y.png?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_800,c_scale\u002Ff_webp,q_auto\u002Fv1793018831\u002Fimages\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y.png?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1793018831\u002Fimages\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y.png?_i=AA 1400w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_200,c_scale\u002Ff_webp,q_auto\u002Fv1793018831\u002Fimages\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y\u002FMRNA-2026-10-26_MRNA_ntm_ps_5y.png?_i=AA 300w\" sizes=\"auto, (max-width: 3024px) 100vw, 3024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Moderna (MRNA): forward (NTM) price\u002Fsales, last 5 years (\u003Cstrong>TIKR\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">At this morning’s price, it’s closer to 39x.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-the-case-for-patience\" class=\"wp-block-heading\">The case for patience\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">David Berman, Moderna’s chief development officer, argued on Saturday’s investor call that the benefit will grow. The vaccine takes weeks to make and weeks more to work, so the two arms of a trial track each other for about six months. In Phase 2, the cut in risk at the same point in follow-up was 44%. It grew to 49% as those early months counted for less.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">“We do believe the phase III data, for this reason, will continue to improve,” he said.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Piper Sandler agrees: this morning it raised its price target to $230 from $167.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Still, analysts expect revenue of just $3.34 billion in 2028, about half of 2023’s $6.85 billion.\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3024\" height=\"2016\" data-public-id=\"images\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028.png\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3024,h_2016,c_scale\u002Ff_webp,q_auto\u002Fv1793018828\u002Fimages\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028.png?_i=AA\" alt=\"Bar chart from TIKR of Moderna's revenue, actual and consensus estimates, $ billions, fiscal 2023–2028.\" class=\"wp-post-145509 wp-image-145508\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1793018828\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1793018828\u002Fimages\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028.png?_i=AA 3024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793018828\u002Fimages\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028.png?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_800,c_scale\u002Ff_webp,q_auto\u002Fv1793018828\u002Fimages\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028.png?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1793018828\u002Fimages\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028.png?_i=AA 1400w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_200,c_scale\u002Ff_webp,q_auto\u002Fv1793018828\u002Fimages\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028\u002FMRNA-2026-10-26_MRNA_revenue_estimates_2023-2028.png?_i=AA 300w\" sizes=\"auto, (max-width: 3024px) 100vw, 3024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Moderna (MRNA): revenue, actual and consensus estimates, $ billions, fiscal 2023–2028 (\u003Cstrong>TIKR\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Nothing in Saturday’s data argues for cutting those estimates.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-great-data-steep-price\" class=\"wp-block-heading\">Great data, steep price\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Moderna sank on “transformational” data because the stock was priced for more than one melanoma win. At close to 39x forward sales, it still is.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">My take: intismeran looks like a real advance for patients, but I’d want the overall-survival data in hand before paying this multiple.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">Of course, if the benefit grows the way Berman expects, today’s price could look cheap in hindsight. Merck reports on Oct. 29, and Moderna on Nov. 6.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-so-what-is-moderna-stock-actually-worth\" class=\"wp-block-heading\">So what is Moderna stock actually worth?\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Moderna could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fvaluation-model-builder?ref=tikrblog\">Value Moderna for free\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch3 id=\"h-disclaimer\" class=\"wp-block-heading\">\u003Cstrong>Disclaimer:\u003C\u002Fstrong>\u003C\u002Fh3>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cem>Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!\u003C\u002Fem>\u003C\u002Fp>\n",774,"en","\u002Fblog\u002Fmoderna-sinks-another-8-even-as-lead-investigator-calls-melanoma-vaccine-data-transformational","moderna-sinks-another-8-even-as-lead-investigator-calls-melanoma-vaccine-data-transformational","images\u002Fgrim-older-man-falling-red-chart\u002Fgrim-older-man-falling-red-chart","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792780116\u002Fimages\u002Fgrim-older-man-falling-red-chart\u002Fgrim-older-man-falling-red-chart.png?_i=AA",{"altText":165,"imageCredit":166},"Moderna Sinks Another 8% Even as Lead Investigator Calls Melanoma Vaccine Data “Transformational”","BackyardProduction from Getty Images via Canva]",{"name":168,"slug":169,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":172},"Roxanna Maglangit","roxtikr","author","",[],{"name":174,"slug":175,"role":176,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":177},"Michael Douglass","MichaelDouglass","editor",[],[179],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},"General Investing","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",0,[],{"title":165,"metaDesc":186,"opengraphDescription":186,"twitterTitle":165,"twitterDescription":186},"A real win for melanoma patients, and still a pricey stock",{"title":153,"description":186,"twitterTitle":153,"twitterDescription":186,"author":168,"articlePublisher":188,"articlePublishedTime":154,"articleModifiedTime":155,"twitterLabel1":189,"twitterData1":190,"ogTitle":153,"ogDescription":186,"ogUrl":160,"ogImage":163,"ogImageWidth":191,"ogImageHeight":192,"ogImageSecureUrl":163,"ogImageAlt":165,"twitterImage":163},"TIKR.com","Est. reading time","5 minutes",1200,630,[194,209,226,241,256],{"id":183,"title":195,"date":196,"excerpt":197,"wordCount":198,"uri":199,"slug":200,"cloudinaryAssetId":201,"featuredImageOriginalUrl":202,"featuredImageMetadata":203,"author":204,"categories":206,"relatedPosts":208},"Lumentum Gains 3% as StoneX Starts at Buy With $1,200 Target: \"Critical Scarcity Points\"","2026-10-26 19:24:22","StoneX isn't going out on a limb here",730,"\u002Fblog\u002Flumentum-gains-3-as-stonex-starts-at-buy-with-1200-target-critical-scarcity-points","lumentum-gains-3-as-stonex-starts-at-buy-with-1200-target-critical-scarcity-points","images\u002Fconfident-man-rising-green-chart\u002Fconfident-man-rising-green-chart","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792770636\u002Fimages\u002Fconfident-man-rising-green-chart\u002Fconfident-man-rising-green-chart.png?_i=AA",{"altText":195},{"name":168,"slug":169,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":205},[],[207],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":210,"date":211,"excerpt":212,"wordCount":213,"uri":214,"slug":215,"cloudinaryAssetId":216,"featuredImageOriginalUrl":217,"featuredImageMetadata":218,"author":219,"categories":223,"relatedPosts":225},"Circle Sinks 7% as Mizuho Warns of \"Marked Risk\" From AI Agents, Cuts Target to $43","2026-10-26 19:07:47","Mizuho asked AI agents where to keep cash, and they didn't pick USDC",701,"\u002Fblog\u002Fcircle-sinks-7-as-mizuho-warns-of-marked-risk-from-ai-agents-cuts-target-to-43","circle-sinks-7-as-mizuho-warns-of-marked-risk-from-ai-agents-cuts-target-to-43","images\u002F5-9_118780a9ab7\u002F5-9_118780a9ab7","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1784630659\u002Fimages\u002F5-9_118780a9ab7\u002F5-9_118780a9ab7.png?_i=AA",{"altText":210},{"name":220,"slug":221,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":222},"Gian Estrada","giantikr",[],[224],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":227,"date":228,"excerpt":229,"wordCount":230,"uri":231,"slug":232,"cloudinaryAssetId":233,"featuredImageOriginalUrl":234,"featuredImageMetadata":235,"author":236,"categories":238,"relatedPosts":240},"Xencor Soars 31% on Kidney Cancer Trial Data Showing \"Impressive Antitumor Activity\"","2026-10-26 18:55:19","Only 11 patients, but what a start",742,"\u002Fblog\u002Fxencor-soars-31-on-kidney-cancer-trial-data-showing-impressive-antitumor-activity","xencor-soars-31-on-kidney-cancer-trial-data-showing-impressive-antitumor-activity","images\u002Fcheering-woman-rising-green-chart\u002Fcheering-woman-rising-green-chart","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793020037\u002Fimages\u002Fcheering-woman-rising-green-chart\u002Fcheering-woman-rising-green-chart.png?_i=AA",{"altText":227},{"name":168,"slug":169,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":237},[],[239],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":242,"date":243,"excerpt":244,"wordCount":245,"uri":246,"slug":247,"cloudinaryAssetId":248,"featuredImageOriginalUrl":249,"featuredImageMetadata":250,"author":251,"categories":253,"relatedPosts":255},"Range Resources Soars 11% on EQT's All-Stock Takeover Creating \"A Must-Own Energy Company\"","2026-10-26 18:53:00","Range holders just became EQT holders, for better or worse",721,"\u002Fblog\u002Frange-resources-soars-11-on-eqts-all-stock-takeover-creating-a-must-own-energy-company","range-resources-soars-11-on-eqts-all-stock-takeover-creating-a-must-own-energy-company","images\u002Fshocked-man-rising-green-chart\u002Fshocked-man-rising-green-chart","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793020221\u002Fimages\u002Fshocked-man-rising-green-chart\u002Fshocked-man-rising-green-chart.png?_i=AA",{"altText":242},{"name":168,"slug":169,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":252},[],[254],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],{"id":183,"title":257,"date":258,"excerpt":259,"wordCount":260,"uri":261,"slug":262,"cloudinaryAssetId":-1,"featuredImageOriginalUrl":263,"featuredImageMetadata":264,"author":265,"categories":267,"relatedPosts":269},"Barclays Still Sees 100% Upside for Oracle. Here's How It Gets to $252","2026-10-26 18:50:58","The math works, just not in a year",746,"\u002Fblog\u002Fbarclays-still-sees-100-upside-for-oracle-heres-how-it-gets-to-252","barclays-still-sees-100-upside-for-oracle-heres-how-it-gets-to-252","https:\u002F\u002Ftikr1.wpengine.com\u002Fwp-content\u002Fuploads\u002F2026\u002F10\u002FOracleStock-600x400.png",{"altText":257},{"name":168,"slug":169,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":266},[],[268],{"name":180,"slug":181,"uri":182,"description":171,"postsCount":183},[],[271,291,306,320],{"id":183,"title":272,"date":273,"excerpt":274,"wordCount":275,"uri":276,"slug":277,"cloudinaryAssetId":278,"featuredImageOriginalUrl":279,"featuredImageMetadata":280,"author":281,"categories":285,"relatedPosts":290},"Up 13% In Last 12 Months, Can Arista Networks Stock Give Better Returns in 2026?","2026-10-26 12:57:00","Arista stock is up 10% in a year. See what TIKR’s Valuation Model says about ANET’s upside, with a $275 price target by December 2028.",1099,"\u002Fblog\u002Farista-networks-stock-valuation-anet-2026","arista-networks-stock-valuation-anet-2026","images\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793010558\u002Fimages\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva\u002FANET-stock-@Jirsak-from-Getty-Images-Pro-via-Canva-@Africa-images-via-Canva.png?_i=AA",{"altText":272},{"name":282,"slug":283,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":284},"Aditya Raghunath","adityatikr",[],[286],{"name":287,"slug":288,"uri":289,"description":171,"postsCount":183},"Valuation","valuation","\u002Fblog\u002Fcategory\u002Fvaluation",[],{"id":183,"title":292,"date":293,"excerpt":294,"wordCount":295,"uri":296,"slug":297,"cloudinaryAssetId":298,"featuredImageOriginalUrl":299,"featuredImageMetadata":300,"author":301,"categories":303,"relatedPosts":305},"Down 48% In Last 12 Months, Can SoFi Stock Give Better Results in 2026?","2026-10-26 12:45:00","SoFi stock is down 51% in a year. See what TIKR’s Valuation Model says about SOFI’s upside, with a $22 price target by December 2028.",1081,"\u002Fblog\u002Fsofi-stock-valuation-sofi-2026","sofi-stock-valuation-sofi-2026","images\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793015325\u002Fimages\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva\u002FSOFI-stock-@AKKI-from-AKKI-JOHN-via-Canva-@MCCAIG-from-Getty-Images-Signature-via-Canva.png?_i=AA",{"altText":292},{"name":282,"slug":283,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":302},[],[304],{"name":287,"slug":288,"uri":289,"description":171,"postsCount":183},[],{"id":183,"title":307,"date":293,"excerpt":308,"wordCount":309,"uri":310,"slug":311,"cloudinaryAssetId":312,"featuredImageOriginalUrl":313,"featuredImageMetadata":314,"author":315,"categories":317,"relatedPosts":319},"Up Just 9% in the Last 12 Months, Can Palantir Stock Give Better Returns in 2026?","Palantir stock is up just 4% in a year. See what TIKR’s Valuation Model says about PLTR’s upside, with a $529 target by December 2028.",1024,"\u002Fblog\u002Fpalantir-stock-valuation-pltr-2026","palantir-stock-valuation-pltr-2026","images\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793003212\u002Fimages\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c\u002FPLTR-stock-@surachet_shotivaranon-from-surachetshs-Images-via-Canva-@SORAPOP-UDOMSRI-from-Sorapop-Udomsri-via-Canva_1454044a26c.png?_i=AA",{"altText":307},{"name":282,"slug":283,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":316},[],[318],{"name":287,"slug":288,"uri":289,"description":171,"postsCount":183},[],{"id":183,"title":321,"date":322,"excerpt":323,"wordCount":324,"uri":325,"slug":326,"cloudinaryAssetId":327,"featuredImageOriginalUrl":328,"featuredImageMetadata":329,"author":330,"categories":332,"relatedPosts":334},"Down 56% In Last 12 Months, Can AppLovin Stock Give Better Returns in 2026?","2026-10-26 12:33:00","AppLovin stock is down 60% in a year. See what TIKR’s Valuation Model says about APP’s upside, with a $366 price target by December 2028.",1139,"\u002Fblog\u002Fapplovin-stock-valuation-app-2026","applovin-stock-valuation-app-2026","images\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1793013215\u002Fimages\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2\u002FAPP-stock-@juststock-from-Getty-Images-via-Canva-@maxkabakov-from-Getty-Images-via-Canva_14548356cd2.png?_i=AA",{"altText":321},{"name":282,"slug":283,"role":170,"roleTitle":171,"biography":171,"avatar":171,"socialMediaLinks":331},[],[333],{"name":287,"slug":288,"uri":289,"description":171,"postsCount":183},[]]